R-Verapamil for the Prophylaxis of Episodic Cluster Headache

Episodic Cluster Headache Clinical Trial

Official title:
A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache

Status Terminated

Clinical Trial Summary

This is a double-blinded, randomized, parallel, placebo-controlled phase 2 study to evaluate the safety and efficacy of R-verapamil in the prophylaxis of episodic cluster headache.

Clinical Trial Description

Approximately 30 subjects (about 15 per treatment group),will be enrolled and randomized to receive either R-verapamil or placebo for 2 weeks. The study will consist of a 1-week run-in period and a 2-week treatment period (R-verapamil or placebo). The total duration of the study for each treatment group is 3 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02209155
Study type	Interventional
Source	Center Laboratories, Inc.
Contact
Status	Terminated
Phase	Phase 2
Start date	November 2013
Completion date	March 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01341548` - Civamide Nasal Solution for Cluster Headache	Phase 3
Unknown status	`NCT00399243` - Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache	Phase 4
Completed	`NCT02397473` - A Study Of Galcanezumab In Participants With Episodic Cluster Headache	Phase 3
Completed	`NCT02797951` - A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache	Phase 3
Completed	`NCT00033839` - A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache	Phase 3
Terminated	`NCT02945046` - A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)	Phase 3
Completed	`NCT00069082` - Intranasal Civamide for Episodic Cluster Headache	Phase 3